Skip to main content
ESLOY logo

EssilorLuxottica S.A. (ESLOY) Stock Price & Analysis

EssilorLuxottica S.A. (ESLOY) — price $96.86 (-2.38%), as of the Nov 19, 2026 trading session; market cap $88.8B.

Educational signal · not a buy or sell recommendation · How to read this

$96.86 −$2.36 (-2.38%) Market Cap $88.8B

EssilorLuxottica S.A. · ESLOY · Healthcare · Medical - Instruments & Supplies

EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • BDX · Becton, Dickinson and Company · 68 /100
  • ISRG · Intuitive Surgical, Inc. · 94 /100
  • MDLN · Medline Inc. Class A Common Stock · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$96.86
Change on the day-2.38%
52-week range$79.27–$181.56
Market capitalisation$88.8B—
Price / earnings (trailing)33.11
Shares traded on the day21.2K
Beta (volatility vs the S&P 500)0.55

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $80, high $185, latest $97. $185 $80 high $185 Oct 17, 2025 Nov 19, 2026 · $97 $183Oct 17, 2025$184Oct 31, 2025$185Nov 14, 2025$179Nov 28, 2025$166Dec 12, 2025$159Dec 26, 2025$162Jan 9, 2026$157Jan 23, 2026$152Feb 6, 2026$140Feb 20, 2026$123Mar 6, 2026$112Mar 20, 2026$110Apr 2, 2026$126Apr 17, 2026$108May 1, 2026$100May 15, 2026$102May 29, 2026$105Jun 12, 2026$96Jun 26, 2026$98Jul 10, 2026$93Jul 24, 2026$100Aug 7, 2026$95Aug 21, 2026$87Sep 4, 2026$80Sep 18, 2026$81Oct 2, 2026$86Oct 16, 2026$103Oct 30, 2026$101Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for EssilorLuxottica (ESLOY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is EssilorLuxottica (ESLOY), and what does it report?

Short answer

EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. Healthcare / Medical Instruments & Supplies SEC filing business address: 147 RUE DE Paris, Charenton LE Pont, I0, 94220. It employs 203,791 people and is led by Francesco Milleri. In Q2 FY2026 it reported revenue of €15.11B and net income of €1.60B. The market values it at $88.8B.

2 · Latest results

What do the latest results show for EssilorLuxottica (ESLOY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of €15.11B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026€15.11B€1.60B€1.72 (diluted)
Q4 FY2025€14.36B€921M€0.98 (diluted)
Q2 FY2025€14.02B€1.39B€1.50 (diluted)
Q4 FY2024€13.22B€994M€1.08 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for EssilorLuxottica (ESLOY)?

Short answer · as of

The distress and quality screens read Altman Z 2.91 · Piotroski F 8. Trailing ratios: ROE 6.4% · ROA 3.8% · current ratio 0.89 · earnings yield 2.9% · free-cash-flow yield 4.5%.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Rich valuation — a P/E of 33.11 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ESLOY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ESLOY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about EssilorLuxottica (ESLOY)?

Read these with our analysis →

Common Questions About ESLOY (Healthcare)

Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

How do Varilux, Crizal and Transitions fit into EssilorLuxottica?

They are prescription-lens technologies within the lenses and optical instruments business, alongside corrective lenses, optician equipment and digital optical solutions. They show why EssilorLuxottica is more than a frame and sunglasses company.

Why does EssilorLuxottica sell laboratory machinery alongside Foster Grant readers?

The company participates across the vision-care chain, supplying consumers with readers while also equipping laboratories and optical manufacturers with surfacing and coating machinery. That combination links consumer brands with business-to-business production infrastructure.

What is the ESLOY stock price today?

The last price recorded for EssilorLuxottica S.A. (ESLOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 14 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: How do Varilux, Crizal and Transitions fit into EssilorLuxottica?: Business description; Sector / industry (provider taxonomy)
  • FAQ: Why does EssilorLuxottica sell laboratory machinery alongside Foster Grant readers?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.